List view / Grid view
28 May 2015 | By Victoria White
Synjardy has been granted marketing authorisation by the European Commission for the treatment of adults with type 2 diabetes (T2D) in the European Union...
28 May 2015 | By Victoria White
The US Food and Drug Administration has approved Boehringer Ingelheim’s once-daily Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray...
21 May 2015 | By Victoria White
New data shows tiotropium/olodaterol Respimat provides lung function benefit to patients with COPD from the start of maintenance therapy...
18 May 2015 | By Victoria White
Boehringer Ingelheim has acquired Pharmaxis’ investigational drug PXS4728A, to develop it for the treatment of NASH and to prevent its consequences...
14 May 2015 | By Victoria White
First AF patient is enrolled in a study assessing the safety and efficacy of uninterrupted anticoagulation with dabigatran during ablation procedures...
30 March 2015 | By Victoria White
BI and Lilly announce they have received a positive opinion from CHMP, recommending empagliflozin/metformin hydrochloride for the treatment type 2 diabetes...
23 March 2015 | By Victoria White
GLYXAMBI® tablets are now available by prescription in the US. GLYXAMBI offers improved glycemic control as an adjunct to diet and exercise...
17 March 2015 | By Victoria White
AF patients considered at high risk for stroke may not be receiving recommended treatment as revealed in analyses from the GLORIA™-AF Registry Program...
4 March 2015 | By Boehringer Ingelheim
Boehringer Ingelheim announces that idarucizumab has been submitted for approval of marketing authorisation to the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA) and Health Canada...
10 February 2015 | By Boehringer Ingelheim
Boehringer Ingelheim, a research-based, global pharmaceutical company, and VTU Technology, a leading contract research and development company, announced today the renewal of their global Pichia pastoris technology collaboration agreement...
3 February 2015 | By Eli Lilly
The U.S. FDA has approved Glyxambi® (empagliflozin/linagliptin) tablets, from Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) when both empagliflozin and linagliptin are appropriate treatments...
19 January 2015 | By Boehringer Ingelheim
Boehringer Ingelheim today announced that the European Commission (EC) has approved nintedanib* for the treatment of idiopathic pulmonary fibrosis (IPF), following an expedited review and positive CHMP opinion on 20 November 2014. Nintedanib* will be marketed in the EU under the brand name OFEV®...
16 December 2014 | By Boehringer Ingelheim
Boehringer Ingelheim announces that the first patient has been enrolled in the RE-SPECT ESUS™ phase III study to investigate the efficacy and safety of dabigatran etexilate for the prevention of recurrent Embolic Stroke of Undetermined Source, also called ESUS...
9 December 2014 | By Boehringer Ingelheim
New data demonstrate that a five-minute infusion of the investigational specific antidote idarucizumab led to immediate, complete and sustained reversal of the anticoagulant effect of Pradaxa® (dabigatran etexilate)...
8 December 2014 | By Boehringer Ingelheim
The unveiling of the new technology centre in Biberach represents the temporary completion of a remodelling and construction phase in chemical development at Boehringer Ingelheim’s largest research and development location...
